Thermo Fisher Scientific Inc. (TMO) is Waters Parkerson & CO. LLC’s 3rd Largest Position

Waters Parkerson & CO. LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 213,495 shares of the medical research company’s stock after selling 1,334 shares during the period. Thermo Fisher Scientific comprises about 3.6% of Waters Parkerson & CO. LLC’s holdings, making the stock its 3rd largest holding. Waters Parkerson & CO. LLC owned about 0.05% of Thermo Fisher Scientific worth $40,393,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of Thermo Fisher Scientific by 2,692.1% during the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after purchasing an additional 22,165,530 shares in the last quarter. Capital Research Global Investors increased its position in shares of Thermo Fisher Scientific by 29.8% during the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after purchasing an additional 3,973,136 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Thermo Fisher Scientific by 2,058.1% during the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after purchasing an additional 2,233,522 shares in the last quarter. Veritas Asset Management LLP increased its position in shares of Thermo Fisher Scientific by 112.4% during the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after purchasing an additional 1,286,259 shares in the last quarter. Finally, Harbour Capital Advisors LLC increased its position in shares of Thermo Fisher Scientific by 18,197.5% during the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock worth $6,884,000 after purchasing an additional 1,194,487 shares in the last quarter. Hedge funds and other institutional investors own 86.16% of the company’s stock.

TMO has been the topic of a number of research analyst reports. Cowen reiterated an “outperform” rating and set a $220.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Leerink Swann lifted their target price on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research report on Monday, October 9th. Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Goldman Sachs Group initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price on the stock. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $205.21.

Shares of Thermo Fisher Scientific Inc. (NYSE TMO) opened at $192.27 on Monday. Thermo Fisher Scientific Inc. has a twelve month low of $139.88 and a twelve month high of $201.20. The firm has a market capitalization of $77,099.31, a P/E ratio of 21.13, a price-to-earnings-growth ratio of 1.76 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same quarter in the previous year, the company earned $2.03 EPS. The firm’s revenue for the quarter was up 13.9% compared to the same quarter last year. equities research analysts forecast that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.

In other news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the sale, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.49% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://stocknewstimes.com/2017/12/18/thermo-fisher-scientific-inc-tmo-is-waters-parkerson-co-llcs-3rd-largest-position.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply